These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel. Kang J, Chen XL, Wang H, Ji J, Cheng H, Incardona J, Reynolds W, Viviani F, Tabart M, Rampe D. Mol Pharmacol; 2005 Mar; 67(3):827-36. PubMed ID: 15548764 [Abstract] [Full Text] [Related]
4. The hERG channel activator, RPR260243, enhances protective IKr current early in the refractory period reducing arrhythmogenicity in zebrafish hearts. Shi YP, Pang Z, Venkateshappa R, Gunawan M, Kemp J, Truong E, Chang C, Lin E, Shafaattalab S, Faizi S, Rayani K, Tibbits GF, Claydon VE, Claydon TW. Am J Physiol Heart Circ Physiol; 2020 Aug 01; 319(2):H251-H261. PubMed ID: 32559136 [Abstract] [Full Text] [Related]
5. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data. Jonker DM, Kenna LA, Leishman D, Wallis R, Milligan PA, Jonsson EN. Clin Pharmacol Ther; 2005 Jun 01; 77(6):572-82. PubMed ID: 15961988 [Abstract] [Full Text] [Related]
7. High affinity open channel block by dofetilide of HERG expressed in a human cell line. Snyders DJ, Chaudhary A. Mol Pharmacol; 1996 Jun 01; 49(6):949-55. PubMed ID: 8649354 [Abstract] [Full Text] [Related]
8. The long QT syndrome: new diagnostic and therapeutic approach in the era of molecular biology. Priori SG, Cantù F, Schwartz PJ. Schweiz Med Wochenschr; 1996 Oct 12; 126(41):1727-31. PubMed ID: 8893413 [Abstract] [Full Text] [Related]
9. Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. Kiehn J, Lacerda AE, Wible B, Brown AM. Circulation; 1996 Nov 15; 94(10):2572-9. PubMed ID: 8921803 [Abstract] [Full Text] [Related]
10. Differential recovery of action potential duration and HERG currents from the effects of two methanesulfonamide class III antiarrhythmic agents, KCB-328 and dofetilide. Lee K, Park JB, Jeon BH, Kim KJ, Ryu PD, Kwon LS, Kim HY. J Cardiovasc Pharmacol; 2003 Nov 15; 42(5):648-55. PubMed ID: 14576514 [Abstract] [Full Text] [Related]
13. Structural determinants of HERG channel block by clofilium and ibutilide. Perry M, de Groot MJ, Helliwell R, Leishman D, Tristani-Firouzi M, Sanguinetti MC, Mitcheson J. Mol Pharmacol; 2004 Aug 15; 66(2):240-9. PubMed ID: 15266014 [Abstract] [Full Text] [Related]
15. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications. Thomas D, Karle CA, Kiehn J. Curr Pharm Des; 2006 Aug 15; 12(18):2271-83. PubMed ID: 16787254 [Abstract] [Full Text] [Related]
19. The Susceptibilities of Human Ether-à-Go-Go-Related Gene Channel with the G487R Mutation to Arrhythmogenic Factors. Hisajima N, Hata Y, Kinoshita K, Fukushima T, Nishida N, Kano M, Tabata T. Biol Pharm Bull; 2015 Aug 15; 38(5):781-4. PubMed ID: 25947924 [Abstract] [Full Text] [Related]
20. Inhibitory effects of AMP 579, a novel cardioprotective adenosine A1/A2A receptor agonist, on native IKr and cloned HERG current. Saegusa N, Sato T, Ogura T, Komuro I, Nakaya H. Naunyn Schmiedebergs Arch Pharmacol; 2004 Dec 15; 370(6):492-9. PubMed ID: 15558241 [Abstract] [Full Text] [Related] Page: [Next] [New Search]